Evidence map›Paper›PMID 38032857›Full record

ArticlePLoS neglected tropical diseases2023

Reduced dengue incidence following city-wide wMel Wolbachia mosquito releases throughout three Colombian cities: Interrupted time series analysis and a prospective case-control study.

Ivan Dario Velez, Stephanie K Tanamas, Maria Patricia Arbelaez, Simon C Kutcher, Sandra L Duque, Alexander Uribe, Lina Zuluaga, Luis Martínez, Ana Cristina Patiño, Jovany Barajas and 15 more

Registry-linked trialAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03631719 (World Mosquito Program - Colombia), which is not on this map. Cited by 48 papers.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03631719 completednot on this map

World Mosquito Program - Colombia (WMP-COLOMBIA): The Impact of City-wide Deployment of Wolbachia-infected Mosquitoes on Arboviral Disease Incidence in Medellin and Bello, Colombia

Typeobservational_patient_registrySponsorUniversidad de AntioquiaRan2017 to 2021Enrolled834ConditionsDengue, Chikungunya Virus Infection, Zika Virus InfectionArmsWolbachia-carrying Ae.aegypti mosquitoes
3 · Its place in the literature

Who cites it

48 citing papers in PubMed.

  1. Trial
  2. Review
  3. Pervasive effects ofbioRxiv : the preprint server for biology · 2026
    Article
  4. Article
  5. bioRxiv : the preprint server for biology · 2026
    Article
  6. Article
  7. Review
  8. Review
  9. Climate predictsbioRxiv : the preprint server for biology · 2026
    Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Larval diet-mediated morphological trait andFrontiers in insect science · 2026
    Article
  15. The inhibition mechanism ofFrontiers in microbiology · 2026
    Review
  16. Article
  17. Article
  18. Long-Term Durability and Public Health Impact of City-WideTropical medicine and infectious disease · 2025
    Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Ivan Dario VelezWorld Mosquito Program, Universidad de Antioquia, Medellín, Colombia.
Stephanie K TanamasWorld Mosquito Program, Monash University, Melbourne, Australia.
Maria Patricia ArbelaezWorld Mosquito Program, Universidad de Antioquia, Medellín, Colombia.
Simon C KutcherWorld Mosquito Program, Monash University, Melbourne, Australia.
Sandra L DuqueWorld Mosquito Program, Universidad de Antioquia, Medellín, Colombia.
Alexander UribeWorld Mosquito Program, Universidad de Antioquia, Medellín, Colombia.
Lina ZuluagaWorld Mosquito Program, Universidad de Antioquia, Medellín, Colombia.
Luis MartínezWorld Mosquito Program, Universidad de Antioquia, Medellín, Colombia.
Ana Cristina PatiñoWorld Mosquito Program, Universidad de Antioquia, Medellín, Colombia.
Jovany BarajasWorld Mosquito Program, Universidad de Antioquia, Medellín, Colombia.
Estefanía MuñozWorld Mosquito Program, Universidad de Antioquia, Medellín, Colombia.
Maria Camila Mejia TorresWorld Mosquito Program, Universidad de Antioquia, Medellín, Colombia.
Sandra UribeWorld Mosquito Program, Universidad de Antioquia, Medellín, Colombia.
Sandra PorrasWorld Mosquito Program, Universidad de Antioquia, Medellín, Colombia.
Rita AlmanzaSecretariat of Health, Medellín, Colombia.
Henry PulidoSecretariat of Health, Bello, Colombia.
Scott L O'NeillWorld Mosquito Program, Monash University, Melbourne, Australia.
Eduardo Santacruz-SanmartinWorld Mosquito Program, Universidad de Antioquia, Medellín, Colombia.
Sandra GonzalezWorld Mosquito Program, Universidad de Antioquia, Medellín, Colombia.
Peter A RyanWorld Mosquito Program, Monash University, Melbourne, Australia.
Jai A DentonWorld Mosquito Program, Monash University, Melbourne, Australia.ORCID 0000-0002-5259-4221
Nicholas P JewellDepartment of Medical Statistics, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Suzanne M DufaultDivision of Biostatistics, Department of Epidemiology and Biostatistics, University of California, San Francisco, California, United States of America.
Cameron P SimmonsWorld Mosquito Program, Monash University, Melbourne, Australia.
Katherine L AndersWorld Mosquito Program, Monash University, Melbourne, Australia.ORCID 0000-0003-0485-5826

Funding

Emerging methods and applications for test-negative studies of of infectious disease interventionsR01AI148127 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI JEWELL, NICHOLAS P · 2020 to 2023
$1.8M
NIAID NIH HHS R01 AI148127Wellcome TrustWellcome Trust 102591/Z/13/A
6 · The paper itself

Abstract

backgroundThe introduction of Wolbachia (wMel strain) into Aedes aegypti mosquitoes reduces their capacity to transmit dengue and other arboviruses. Randomised and non-randomised studies in multiple countries have shown significant reductions in dengue incidence following field releases of wMel-infected Ae. aegypti. We report the public health outcomes from phased, large-scale releases of wMel-Ae. aegypti mosquitoes throughout three contiguous cities in the Aburrá Valley, Colombia. METHODOLOGY/PRINCIPAL

findingsFollowing pilot releases in 2015-2016, staged city-wide wMel-Ae. aegypti deployments were undertaken in the cities of Bello, Medellín and Itagüí (3.3 million people) between October 2016 and April 2022. The impact of the Wolbachia intervention on dengue incidence was evaluated in two parallel studies. A quasi-experimental study using interrupted time series analysis showed notified dengue case incidence was reduced by 95% in Bello and Medellín and 97% in Itagüí, following establishment of wMel at ≥60% prevalence, compared to the pre-intervention period and after adjusting for seasonal trends. A concurrent clinic-based case-control study with a test-negative design was unable to attain the target sample size of 63 enrolled virologically-confirmed dengue (VCD) cases between May 2019 and December 2021, consistent with low dengue incidence throughout the Aburrá Valley following wMel deployments. Nevertheless, VCD incidence was 45% lower (OR 0.55 [95% CI 0.25, 1.17]) and combined VCD/presumptive dengue incidence was 47% lower (OR 0.53 [95% CI 0.30, 0.93]) among participants resident in wMel-treated versus untreated neighbourhoods. CONCLUSIONS/SIGNIFICANCE: Stable introduction of wMel into local Ae. aegypti populations was associated with a significant and sustained reduction in dengue incidence across three Colombian cities. These results from the largest contiguous Wolbachia releases to-date demonstrate the real-world effectiveness of the method across large urban populations and, alongside previously published results, support the reproducibility of this effectiveness across different ecological settings.

trial registrationNCT03631719.

Indexed as

AedesDengueDengue VirusWolbachiaAnimalsCase-Control StudiesCitiesColombiaHumansIncidenceInterrupted Time Series AnalysisMosquito VectorsPest Control, BiologicalReproducibility of Results

Identifiers

PMID38032857
PMCPMC10688673

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.